

CLAIMS

1. Crystalline compound of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has diffraction peaks at the diffraction angles ( $2\theta$ ) of:  $4.7 \pm 0.1^\circ$ ,  $7.4 \pm 0.1^\circ$ ,  $11.8 \pm 0.1^\circ$ ,  $13.4 \pm 0.1^\circ$ ,  $16.5 \pm 0.1^\circ$ , and  $18.6 \pm 0.1^\circ$  in a powder X-ray diffraction pattern.
2. The crystalline compound according to claim 1, which has endothermic peaks approximately at  $170 - 190^\circ\text{C}$  and  $225^\circ\text{C}$  in a DSC chart obtained in differential scanning calorimetry (DSC).
3. A composition comprising the crystalline compound according to claim 1 or 2.
4. A pharmaceutical composition comprising the crystalline compound according to claim 1 or 2.
5. An antiallergic medicine comprising the crystalline compound according to claim 1 or 2.
6. Use of the crystalline compound according to claim 1 or 2 for the production of a pharmaceutical composition.
7. Use of the crystalline compound according to claim 1 or 2 for the production of an antiallergic medicine.
8. A method for preventing or treating an allergic disease, comprising administering the crystalline compound according to claim 1 or 2 to an animal including a human.